Interview with Ala Ciobanu, General Manager, Roche Ukraine
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
Address: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Welwyn Garden City, Hertfordshire, AL7 1TW, United Kingdom
Tel: +44 (0)1707 366000
Web: http://www.roche.co.uk/portal/uk
Headquartered in Basel, Switzerland, Roche employs around 2,000 people in the UK in pharmaceuticals, based at Welwyn Garden City in Hertfordshire, and diagnostics, based at Burgess Hill in East Sussex.
The UK pharmaceuticals headquarters at Welwyn Garden City in Hertfordshire is home to Roche’ global pharmaceutical product development team, its pharmaceuticals sales and marketing teams and corporate functions.
The purpose built facility that opened in 2005 at Shire Park in Welwyn Garden City, reflects and supports the continued success of Roche’s pharmaceutical business.
In 2006 Roche’ UK diagnostics sales and marketing team relocated to a new purpose-built facility in Burgess Hill, East Sussex.
As the UK’s leading in-vitro diagnostics company, Roche has a dynamic UK sales and marketing team who consistently deliver growth above the market rate.
As one of the major pharmaceutical and diagnostic companies in the UK, Roche develops and provides an innovative range of products and services that help healthcare professionals improve the health and well-being of the UK population.
As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company?…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
